| Project/Area Number |
09470197
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Gunma University |
|---|
Principal Investigator |
ENDO Keigo Gunma University School of Medicine, Department of Nuclear Medicine, Professor, 医学部, 教授 (10115800)
|
|---|
| Project Period (FY) |
1997 – 1998
|
| Project Status |
Completed (Fiscal Year 1998)
|
| Budget Amount *help |
¥6,400,000 (Direct Cost: ¥6,400,000)
Fiscal Year 1998: ¥2,700,000 (Direct Cost: ¥2,700,000)
Fiscal Year 1997: ¥3,700,000 (Direct Cost: ¥3,700,000)
|
|---|
| Keywords | genetic engineering / technetium-99m / monoclonal antibody / peptide / white blood cell / indium-111 / rhenium-186 / インジウム-111 / 単クローン抗体 / 白血球 |
|---|
| Research Abstract |
This research project was performed to develop new diagnostic and therapeutic radiopharmaceuticals using radiolabeled peptides.
By employing the genetic engineering, murine monoclonal antibodies reactive with white blood cells were analyzed and humanized for clinical use, in order to decrease the immunogenecity of murine type antibody. Technetium-99m labeled humanized antibodies were safely administered to patients with various diseases after getting the permission of ethical committee of our institute. 99mTc-labeled humanized antibodies localized in the normal bone marrow and metastic bones were demonstrated as acold area. Comparing to the original murine antibodies the production of anti-murine antidoby in patients' serum were neglible and 99mTc-labeled humanized antibodies will be a promising reagent for the detection of bone metastasis and also for the infectious regions. However, peptides radiolabeled with radionuclides were easily aggregated and remains to be investigated.
|
